Cerquetti Marina, Cardines Rita, Giufrè Maria, Mastrantonio Paola
Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
J Antimicrob Chemother. 2004 Dec;54(6):1139-43. doi: 10.1093/jac/dkh467. Epub 2004 Oct 14.
Haemophilus influenzae invasive disease is potentially life threatening and requires prompt antibiotic therapy. The aim of this study was to assess the antimicrobial susceptibility of H. influenzae strains isolated from invasive disease in Italy and to investigate ampicillin-resistant isolates by molecular biology techniques.
One-hundred and seventy-six invasive H. influenzae isolates, collected during 1998-2003, were analysed for susceptibility to ampicillin, azithromycin, chloramphenicol and ciprofloxacin. Ampicillin-resistant isolates were further tested against cefotaxime and imipenem. MICs were determined by Etest and interpreted according to NCCLS criteria. The ampicillin resistance genes, bla(TEM) and bla(ROB), were searched for by PCR. Genetic relatedness among ampicillin-resistant isolates was investigated by PFGE.
Overall, ampicillin resistance was 10.2% (all beta-lactamase producer strains). The prevalence of ampicillin-resistant isolates increased from 6.9% in 1998/1999 to 19% in 2002/2003. Resistance to azithromycin and chloramphenicol was 6.8% and 1.7%, respectively. No strains were resistant to ciprofloxacin. Co-resistance between ampicillin and chloramphenicol and between ampicillin and azithromycin was observed in three and one isolates, respectively. All ampicillin-resistant isolates were susceptible to cefotaxime and imipenem and all harboured the bla(TEM) gene. PFGE demonstrated that most of the ampicillin-resistant isolates showed little genetic homology.
An upward trend in resistance to ampicillin due to beta-lactamase production was demonstrated In Italy. According to PFGE results, clonal dissemination of ampicillin-resistant isolates does not occur. Imipenem may represent an appropriate alternative for treatment of H. influenzae invasive disease caused by ampicillin-resistant isolates when third-generation cephalosporins cannot be used.
流感嗜血杆菌侵袭性疾病可能危及生命,需要及时进行抗生素治疗。本研究的目的是评估从意大利侵袭性疾病中分离出的流感嗜血杆菌菌株的抗菌药敏性,并通过分子生物学技术研究耐氨苄西林的分离株。
分析1998年至2003年期间收集的176株侵袭性流感嗜血杆菌分离株对氨苄西林、阿奇霉素、氯霉素和环丙沙星的药敏性。对耐氨苄西林的分离株进一步检测其对头孢噻肟和亚胺培南的药敏性。通过Etest测定最低抑菌浓度(MIC),并根据美国国家临床实验室标准委员会(NCCLS)标准进行解读。通过聚合酶链反应(PCR)寻找氨苄西林耐药基因bla(TEM)和bla(ROB)。通过脉冲场凝胶电泳(PFGE)研究耐氨苄西林分离株之间的遗传相关性。
总体而言,氨苄西林耐药率为10.2%(所有产β-内酰胺酶菌株)。耐氨苄西林分离株的患病率从1998/1999年的6.9%上升至2002/2003年的19%。对阿奇霉素和氯霉素的耐药率分别为6.8%和1.7%。无菌株对环丙沙星耐药。分别在3株和1株分离株中观察到氨苄西林与氯霉素以及氨苄西林与阿奇霉素之间的共同耐药。所有耐氨苄西林分离株对头孢噻肟和亚胺培南敏感,且均携带bla(TEM)基因。PFGE显示大多数耐氨苄西林分离株几乎没有遗传同源性。
在意大利,已证明由于产β-内酰胺酶导致对氨苄西林的耐药呈上升趋势。根据PFGE结果,耐氨苄西林分离株不会发生克隆传播。当不能使用第三代头孢菌素时,亚胺培南可能是治疗由耐氨苄西林分离株引起的流感嗜血杆菌侵袭性疾病的合适替代药物。